Metabolism of antipyrine and sulphadimidine in dwarf goats: effects of the enzyme-inducing agents phenobarbital, troleandomycin and rifampicin

References

• Babany G., Larrey D., Pessayre D. Macrolide antibiotics as inducers and inhibitors of cytochrome P-450 in experimental animals and man. Progress in Drug Metabolism, G. G. Gibson. Taylor & Francis, London 1988; vol. 11: 61–98
   Google Scholar
• Belpaire F., Rosseel M. T., Bogaert M. G., DeRick A., D'Heer F. Enhanced serum binding of propranolol and oxprenolol and microsomal induction by rifampicin in the dog. Biochemical Pharmacology 1982; 32: 1122–1125
   Google Scholar
• Berecky I. Interakcia fenobarbitalu resp. hydrokortizónu so sulfadimidinom u oviec (Interaction of phenobarbital and /or hydrocortisone with sulphadimidine in sheep) (Abstract in English). Bioligizace og Chemizace Veterinaria (Praha) 1983; 19: 379–383
   Google Scholar
• Bötcher J., Bassman H., Schuppel R. Quantitation and pattern of 4,4′-dihydroxy-antipyrine, 4-hydroxy-antipyrine and 3-hydroxymethyl-antipyrine as main metabolites of antipyrine in man and rat. Journal of Pharmacy and Pharmacology 1982; 34: 168–175
   PubMedGoogle Scholar
• Danhof M., Breimer D. D. Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. British Journal of Clinical Pharmacology 1979; 8: 529–537
   PubMed Web of Science ®Google Scholar
• Danhof M., Krom D. P., Breimer D. D. Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. Xenobiotica 1979; 9: 695–702
   PubMed Web of Science ®Google Scholar
• Danhof M., Verbeek R. M. A., Van Boxtel C. J., Boeijinga K. J., Breimer D. D. Differential effects of enzyme induction on antipyrine metabolite formation. British Journal of clinical Pharmacology 1982; 13: 379–386
   PubMed Web of Science ®Google Scholar
• Delaforge M., Sartori E. In vivo effects of erythromycin, oleandomycin and erythralosamine derivatives on hepatic cytochrome P450. Biochemical Pharmacology 1990; 40: 223–228
   PubMed Web of Science ®Google Scholar
• Ludden T. M. Pharmacokinetic interactions of the macrolide antibiotics. Clinical Pharmacokinetics 1985; 10: 63–79
   PubMed Web of Science ®Google Scholar
• Metzler C. M., Elfring G. L., McEwen A. J. A package of computer programs for pharmacokinetic modeling. Biometrics 1974; 30: 562–563
   Web of Science ®Google Scholar
• Miller J. F., Clark C. R., Gee S. J., Krieger R. I. Antipyrine plasma half-life, in vivo indicator of oxidative metabolic capability in Rhesus Monkeys (Macaca mulatta). Pharmacology 1978; 16: 279–286
   PubMed Web of Science ®Google Scholar
• Nielsen P. The metabolism of four sulphonamides in cows. Biochemical Journal 1973; 136: 1036–1045
   Google Scholar
• Nouws J. F. M., Meesen B. P. W., Van Gogh H., Korstanje C., Van Miert A. S. J. P. A. M. The effect of testosterone and rutting on the metabolism and pharmacokinetics of sulphadimidine in goats. Journal of Veterinary Pharmacology and Therapeutics 1988; 11: 145–154
   PubMedGoogle Scholar
• Nouws J. F. M., Watson A. D. J., Van Miert A. S. J. P. A. M., Degen M., Van Gogh H., Vree T. B. Pharmacokinetics and metabolism of sulphadimidine in kids at 12 and 18 weeks of age. Journal of Veterinary Pharmacology and Therapeutics 1989; 12: 19–24
   PubMedGoogle Scholar
• Ohnhaus E. E., Park B. K. Measurement of urinary 6-beta-hydrocortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. European Journal of Clinical Pharmacology 1979; 15: 139–145
   PubMed Web of Science ®Google Scholar
• Pineau T., Galtier P., Bonfils C., Derancourt J., Maurel P. Purification of a sheep liver cytochrome P450 from the P450IIIA gene subfamily. Biochemical Pharmacology 1990; 39: 901–909
   PubMedGoogle Scholar
• Rhodes J. C., Houston J. B. Antipyrine metabolite kinetics in phenobarbital and β-naphthoflavone-induced rats. Drug Metabolism and Disposition 1983; 11: 131–136
   PubMed Web of Science ®Google Scholar
• Teunissen M. W. E., Van Der Meerburg-Torren J. E., Vermeulen N. P. E., Breimer D. D. Automated HPLC-determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4′-dihydroxy-antipyrine. Journal of Chromatography (Biomedical Applications) 1983a; 278: 367–378
   PubMed Web of Science ®Google Scholar
• Teunissen M. W. E., Van Graft M., Vermeulen N. P. E., Breimer D. D. Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. Xenobiotica 1983b; 13: 497–502
   PubMed Web of Science ®Google Scholar
• Teunissen M. W. E., Bakker W., Meerburg-Van Der Torren J. E., Breimer D. D. Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. British Journal of Clinical Pharmacology 1984; 18: 701–706
   PubMed Web of Science ®Google Scholar
• Toverud E.-L., Boobis A. R., Brodie M. J., Murray S., Bennett P. N., Whitmarsh V., Davies D. S. Differential induction of antipyrine metabolism by rifampicin. European Journal of Clinical Pharmacology 1981; 21: 155–160
   PubMed Web of Science ®Google Scholar
• Tuffenkji A. E., Alvinerie M., Pineau T., Boulard C., Galtier P. Incidence of a subclinical fascioliasis on antipyrine clearance and metabolite excretion in sheep. Xenobiotica 1988; 18(4): 357–364
   Google Scholar
• Van Den Broek J. M., Teunissen M. W. E., Breimer D. D. Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig. Drug Metabolism and Disposition 1981; 9: 541–544
   PubMed Web of Science ®Google Scholar
• Van Gogh H. Pharmacokinetics of nine sulphonamides in goats. Journal of Veterinary Pharmacology and Therapeutics 1980; 3: 69–81
   Google Scholar
• Van Gogh H., Watson A. D. J., Nouws J. F. M., Nieuwenhuijs J., Van Miert A. S. J. P. A. M. Effect of tick-borne fever (Ehrlichia phagocytophila) and trypanosomiasis (Trypanosoma brucei 1066) on the pharmacokinetics of sulphadimidine and its metabolites in goats. Drug Metabolism and Disposition 1989; 17: 1–6
   PubMed Web of Science ®Google Scholar
• Van't Klooster G. A. E., Van Seeventer P. B., Kolker H. J., Smit L. A., Witkamp R. F. High-performance liquid chromatographic method for the routine determination of sulphadimidine, its hydroxy metabolites and N4-acetyl sulphadimidine in body fluids and cell culture media. Journal of Chromatography. (Biomedical Applications) 1991; 571: 157–168
   PubMedGoogle Scholar
• Van Miert A. S. J. P. A. M., Peters R. H. M., Basudde C. D. K., Nijmeijer S. M., Van Duin C. T. M., van Goch H., Korstanje C. Effect of trenbolone and testosterone on the plasma elimination rates of sulfamethazine, trimethoprim and antipyrine in female dwarf goats. American Journal of Veterinary Research 1988; 49: 2060–2064
   PubMed Web of Science ®Google Scholar
• Vesell E. S. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clinical Pharmacology and Therapeutics 1979; 26(3)275–286
   PubMedGoogle Scholar
• Vickers F. F., Bowman T. A., Dvorchik B. H., Passananti G. T., Hughes D. M., Vesell E. S. On the antipyrine test in laboratory animals, studies in the dog and monkey. Drug Metabolism and Disposition 1989; 17: 160–165
   PubMedGoogle Scholar
• Vree T. B., Hekster Y. A., Tijhuis M. W. Pharmacokinetics of sulfonamides in animals, in: Pharmacokinetics of Sulfonamides Revised. Antibiotics and Chemotherapy 1985; 34: 121–168, T. B. Vree and Y. A. Hekster
   Google Scholar
• Witkamp R. F., Lohuis J. A. C. M., Nijmeijer S. M., Kolker H. J., Van Miert A. S. J. P. A. M. Species- and sex-related differences in the plasma clearance and metabolite formation of antipyrine. A comparative study in four animal species: cattle, goat, rat and rabbit. Xenobiotica 1991; 21: 1483–1492
   PubMed Web of Science ®Google Scholar
• Zilly W., Breimer D. D., Richter E. Pharmacokinetic interactions with rifampicin. Clinical Pharmacokinetics 1977; 2: 61–70
   PubMed Web of Science ®Google Scholar